Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman
SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the...
SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.